ORPHA:468684
CCDC115-CDG
Also known as: CDG syndrome type IIo · CDG-IIo · CDG2O · Carbohydrate deficient glycoprotein syndrome type IIo · Congenital disorder of glycosylation type 2o · Congenital disorder of glycosylation type IIo
Publications
134
51.9th percentile
Trials
0
Interventional, condition-specific
Researchers
281
Distinct authors in sample
Gene link
VMA22
Definitive
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare disorder of glycosylation characterized by onset of , liver failure, , and global . Mild features and have also been reported. Laboratory abnormalities include elevated liver enzymes, mild hypercholesterolemia, and low serum ceruloplasmin.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0014789
- OMIM:616828
- UMLS:C4225191
Additional Mondo synonyms (4)
carbohydrate deficient glycoprotein syndrome type IIo · congenital disorder of glycosylation type 2o · congenital disorder of glycosylation type IIo · congenital disorder of glycosylation, type IIo
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Definitive — VMA22
- LiteraturePresent
134 matched papers (68 in last 10 years) Source
- Phenotype characterisedPresent
23 HPO annotations (e.g. Hepatic failure; Seizure; Abnormal glycosylation) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (VMA22).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
23
Associated phenotypes · MONDO:0014789
- Hepatic failure
- Seizure
- Abnormal glycosylation
- Prolonged neonatal jaundice
- Skeletal muscle atrophy
Showing 5 of 23 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
134
134 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
134 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
68 in the last 10 years · medium confidence · 51.9th percentile (publications denominator)
Phrase hits: 43 · MeSH hits: 0
Who's working on it?
281
Distinct author names in 43 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Morava E13 papers · 2026
Department of Clinical Genomics, Mayo Clinic, Rochester, Minnesota, USA.
Papers in Europe PMC - 02Lefeber DJ8 papers · 2022
Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands.
Papers in Europe PMC - 03Jaeken J7 papers · 2024
Department of Development and Regeneration, Centre for Metabolic Disease, University Hospital Gasthuisberg, KU Leuven, Leuven, Belgium.
Papers in Europe PMC - 04Witters P6 papers · 2024
Department of Paediatrics and Metabolic Center, University Hospitals Leuven, Leuven, Belgium.
Papers in Europe PMC - 05Edmondson AC4 papers · 2024
Division of Human Genetics, Department of Pediatrics, Children's Hospital of Philadelphia, PA, USA.
Papers in Europe PMC - 06Freeze HH4 papers · 2024
Human Genetics Program, Sanford Children's Health Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States.
Papers in Europe PMC - 07He M4 papers · 2026
Division of Human Genetics, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA.
Papers in Europe PMC - 08Bruneel A3 papers · 2020
Department of Biochemistry, Assistance Publique-Hôpitaux de Paris, Bichat Hospital, Paris, France.
Papers in Europe PMC - 09Dos Reis Ferreira V3 papers · 2024
UCIBIO - Applied Molecular Biosciences Unit, Department of Life Sciences, NOVA School of Science and Technology, Universidade NOVA de Lisboa, Caparica, Portugal. sindromecdg@gmail.com.
Papers in Europe PMC - 10Francisco R3 papers · 2024
UCIBIO, Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, Lisboa, Portugal.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
medium confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for CCDC115-CDG — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("CCDC115-CDG" OR "CDG syndrome type IIo" OR "CDG-IIo" OR "CDG2O" OR "Carbohydrate deficient glycoprotein syndrome type IIo" OR "Congenital disorder of glycosylation type 2o" OR "Congenital disorder of the glycosylation type 2o" OR "Congenital disorder of glycosylation type IIo" OR "Congenital disorder of the glycosylation type IIo" OR "congenital disorder of glycosylation, type IIo" OR "congenital disorder of the glycosylation, type IIo") OR ("VMA22" OR "VMA22 syndrome" OR "VMA22-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"CCDC115-CDG" OR "CDG syndrome type IIo" OR "CDG-IIo" OR "CDG2O" OR "Carbohydrate deficient glycoprotein syndrome type IIo" OR "Congenital disorder of glycosylation type 2o" OR "Congenital disorder of the glycosylation type 2o" OR "Congenital disorder of glycosylation type IIo" OR "Congenital disorder of the glycosylation type IIo" OR "congenital disorder of glycosylation, type IIo" OR "congenital disorder of the glycosylation, type IIo"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T17:04:58.612Z